keyword
MENU ▼
Read by QxMD icon Read
search

Micronized progesterone

keyword
https://www.readbyqxmd.com/read/29071830/-hormonal-treatments-and-venous-thrombosis-in-women
#1
Justine Hugon-Rodin, Marc Blondon, Julie Bénard, Geneviève Plu-Bureau, Isabelle Streuli
Venous thromboembolism is frequently associated with hormonal factors in women. A thorough medical history taking of vascular risks and an individual evaluation of the risk-benefit ratio should precede any prescription of hormonal therapies. In contrary to progestin-only-pills, estroprogestative contraceptives increase 3-6 times the risk of venous thrombosis. In assisted reproductive techniques, venous thrombosis is frequently associated with the occurrence of a severe ovarian hyperstimulation syndrome. Antagonist ovarian stimulation protocols lower the risk of hyperstimulation and should therefore be preferred...
October 25, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29040638/low-serum-progesterone-on-the-day-of-embryo-transfer-is-associated-with-a-diminished-ongoing-pregnancy-rate-in-oocyte-donation-cycles-after-artificial-endometrial-preparation-a-prospective-study
#2
E Labarta, G Mariani, N Holtmann, P Celada, J Remohí, E Bosch
STUDY QUESTION: Is there a relationship between serum progesterone (P) and endometrial volume on the day of embryo transfer (ET) with ongoing pregnancy rate (OPR) in artificial endometrium preparation cycles? SUMMARY ANSWER: Patients with serum P < 9.2 ng/ml on the day of ET had a significantly lower OPR but endometrial volume was not related with OPR. WHAT IS KNOWN ALREADY: A window of optimal serum P levels during the embryo implantation period has been described in artificial endometrium preparation cycles...
October 13, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28994639/migraine-menopause-and-hormone-replacement-therapy
#3
E Anne MacGregor
Perimenopause marks a period of increased migraine prevalence in women and many women also report troublesome vasomotor symptoms. Migraine is affected by fluctuating estrogen levels with evidence to support estrogen 'withdrawal' as a trigger of menstrual attacks of migraine without aura, while high estrogen levels can trigger migraine aura. Maintaining a stable estrogen environment with estrogen replacement can benefit estrogen-withdrawal migraine particularly in women who would also benefit from relief of vasomotor symptoms...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28989916/use-of-progesterone-supplement-therapy-for-prevention-of-preterm-birth-review-of-literatures
#4
REVIEW
Suk-Joo Choi
Preterm birth (PTB) is one of the most common complications during pregnancy and it primarily accounts for neonatal mortality and numerous morbidities including long-term sequelae including cerebral palsy and developmental disability. The most effective treatment of PTB is prediction and prevention of its risks. Risk factors of PTB include history of PTB, short cervical length (CL), multiple pregnancies, ethnicity, smoking, uterine anomaly and history of curettage or cervical conization. Among these risk factors, history of PTB, and short CL are the most important predictive factors...
September 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28959636/ovarian-protection-in-cyclophosphamide-treated-mice-by-fennel
#5
Azam Hassanpour, Shirin Yousefian, Majid Askaripour, Fariba Sharififar, Massood Ezzatabadipour
Evaluation of protective effect of fennel on mouse ovary against the destructive effects of cyclophosphamide (CP) was the aim of this study. Adult female NMARI mice were randomly divided into six groups (n = 8): (A) negative control, (B) CP200 mg/kg, (C) fennel 400 mg/kg/day, (E, F, and D) that received fennel 200, 400 and 100 mg/kg/day respectively + CP200 mg/kg. Their ovary weight, volume, and diameter (WVD) were measured. Five micron sections were stained using the H&E method. The serum levels of oestrogen and progesterone were measured using ELISA kit...
2017: Toxicology Reports
https://www.readbyqxmd.com/read/28956650/mucoadhesive-tablets-for-the-vaginal-delivery-of-progesterone-in-vitro-evaluation-and-pharmacokinetics-pharmacodynamics-in-female-rabbits
#6
Abeer S Hassan, Ghareb M Soliman, Marwa F Ali, Mona M El-Mahdy, Gamal El-Din A El-Gindy
OBJECTIVE: To develop mucoadhesive tablets for the vaginal delivery of progesterone (P4) to overcome its low oral bioavailability resulting from drug hydrophobicity and extensive hepatic metabolism. METHODS: The tablets were prepared using mixtures of P4/Pluronic(®) F-127 solid dispersion and different mucoadhesive polymers. The tablets physical properties, swelling index, mucoadhesion and drug release kinetics were evaluated. P4 pharmacokinetic and pharmacodynamic properties were evaluated in female rabbits and compared with vaginal micronized P4 tablets and intramuscular (IM) P4 injection, respectively...
October 23, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/28949010/the-value-of-oral-micronized-progesterone-in-the-prevention-of-recurrent-spontaneous-preterm-birth-a-randomized-controlled-trial
#7
Sherif Ashoush, Osama El-Kady, Gehan Al-Hawwary, Ahmed Othman
INTRODUCTION: Progesterone is becoming universally accepted for preventing recurrent spontaneous preterm delivery. There is, however, poor consensus on the effective types and doses of progesterone to be used. Despite the encouraging available research, the role of oral micronized progesterone has not yet been thoroughly investigated. MATERIAL AND METHODS: We randomized 212 singleton pregnancies with past history of spontaneous preterm delivery at <37 weeks, into a progesterone group (receiving 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks until 37 weeks or delivery) and an identical placebo group...
September 26, 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28938733/a-phase-iii-randomized-controlled-trial-comparing-the-efficacy-safety-and-tolerability-of-oral-dydrogesterone-versus-micronized-vaginal-progesterone-for-luteal-support-in-in-vitro-fertilization
#8
Herman Tournaye, Gennady T Sukhikh, Elke Kahler, Georg Griesinger
No abstract text is available yet for this article.
October 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28926762/progesterone-for-smoking-relapse-prevention-following-delivery-a-pilot-randomized-double-blind-study
#9
Ariadna Forray, Kathryn Gilstad-Hayden, Cristine Suppies, Debra Bogen, Mehmet Sofuoglu, Kimberly A Yonkers
INTRODUCTION: Close to half of women who were smokers prior to conception quit smoking in pregnancy, when endogenous progesterone levels are high. However, at least half resume pre-pregnancy smoking levels within weeks after delivery and when progesterone levels drop. The current pilot study tested the feasibility and preliminary efficacy of postpartum progesterone replacement in preventing relapse to smoking in postpartum women with a history of pre-pregnancy smoking. METHODS: This was an 8-week, double-blind, parallel, randomized, placebo-controlled pilot trial of 41 women with a history of pre-pregnancy smoking who achieved abstinence by 32 weeks of gestation...
December 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28863997/micronized-progesterone-pretreatment-affects-the-inflammatory-response-of-human-gestational-tissues-and-the-cervix-to-lipopolysaccharide-stimulation
#10
Tai-Ho Hung, Szu-Fu Chen, Chung-Pu Wu, Meng-Jen Li, Yi-Lin Yeh, T'sang-T'ang Hsieh
INTRODUCTION: Vaginal administration of micronized progesterone (utrogestan capsule, UG) reduces the risk of preterm birth (PTB) in asymptomatic women with a sonographic short cervix at mid-trimester or with a prior history of spontaneous PTB; however, its exact mechanisms remain unclear. We hypothesized that UG limits the inflammatory processes within the gestational tissues and the cervix. METHODS: Fetal membranes and villous tissues were obtained from normal term placentas from women with cesarean delivery before labor onset...
September 2017: Placenta
https://www.readbyqxmd.com/read/28846767/effects-of-oral-vs-transdermal-estrogen-therapy-on-sexual-function-in-early-postmenopause-ancillary-study-of-the-kronos-early-estrogen-prevention-study-keeps
#11
MULTICENTER STUDY
Hugh S Taylor, Aya Tal, Lubna Pal, Fangyong Li, Dennis M Black, Eliot A Brinton, Matthew J Budoff, Marcelle I Cedars, Wei Du, Howard N Hodis, Rogerio A Lobo, JoAnn E Manson, George R Merriam, Virginia M Miller, Frederick Naftolin, Genevieve Neal-Perry, Nanette F Santoro, Sherman M Harman
Importance: Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition. Objective: To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women. Design, Setting, and Participants: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women...
October 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28815355/egg-donation-of-vitrified-oocytes-bank-produces-similar-pregnancy-rates-by-blastocyst-transfer-when-compared-to-fresh-cycle
#12
Thais S Domingues, Ana Paula Aquino, Bruna Barros, Raquel Mazetto, Mariana Nicolielo, Carolina M Kimati, Talita Devecchi, Tatiana C S Bonetti, Paulo C Serafini, Eduardo L A Motta
PURPOSE: Advances in reproductive techniques, mainly the introduction of oocyte vitrification, have provided the opportunity to conceive from oocyte banks. The aim of this study was to compare the clinical outcomes of fresh and vitrified oocytes in an egg donation program following blastocyst transfer. METHODS: This retrospective observational study included 504 oocyte donation cycles. All donor women were younger than 30 years of age. The recipient cycles were divided into two groups: fresh oocytes (n = 78) or vitrified oocytes (n = 426)...
August 16, 2017: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/28777967/optimal-routes-of-administration-vehicles-and-timing-of-progesterone-treatment-for-inhibition-of-delivery-during-pregnancy
#13
Dajun Fang, Mario Moreno, Robert E Garfield, Ruben Kuon, Huimin Xia
OBJECTIVES: Progestins, notably progesterone (P4) and 17 alpha hydroxyprogesterone caproate, are presently used to treat pregnant women at risk of preterm birth. The aim of this study was to assess the optimal treatment options for progesterone (P4) to delay delivery using a sensitive bioassay for progesterone. STUDY DESIGN: Pregnant rats, known to be highly sensitive to progestins, were treated with P4, including Prochieve(®) (also known as Crinone(®)), in various vehicles from day 13 of gestation and in late gestation, days 19 to 22, and delivery times noted...
September 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28715800/the-efficacy-of-dienogest-in-the-treatment-of-simple-endometrial-hyperplasia-without-atypia
#14
Gulsum Uysal, Gokhan Acmaz, Yusuf Madendag, Fulya Cagli, Hatice Akkaya, Ilknur Madendag, Eda Ulku Karakilic
AIM: The aim of the study was to compare the effectiveness of dienogest (DIE), depo medroxyprogesterone 17-acetate (MPA), and micronized progesteron (MP) regimens for treatment of simple endometrial hyperplasia (EH) without atypia. METHODS: One hundred and twenty premenopausal patients aged between 35 and 55, with simple EH without atypia, were offered 3 types of progestins (MPA, MP, and DIE) and were randomized to one of them. After 6 months of treatment, patients were reevaluated...
July 15, 2017: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/28609128/the-effect-of-different-progestogens-on-sleep-in-postmenopausal-women-a-randomized-trial
#15
Ekachai Leeangkoonsathian, Tawiwan Pantasri, Somsak Chaovisitseree, Nuntana Morakot
BACKGROUND: While progesterone affects sleep, different types of it might affect sleep differently. METHODS: One hundred Thai women, who complained of insomnia, visited the Menopause Clinic at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand from February 2014 to March 2015, and were divided randomly into two groups. Both groups received daily hormonal treatment that included estradiol valerate (progynova) at 1 mg. The first group also received dydrogesterone (duphaston(®)) at 10 mg and the second group micronized progesterone (utrogestran(®)) at 100 mg...
June 13, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28502186/effectiveness-of-dydrogesterone-17-oh-progesterone-and-micronized-progesterone-in-prevention-of-preterm-birth-in-women-with-a-short-cervix
#16
Olga Pustotina
OBJECTIVE: To compare the efficacy of dydrogesterone, 17-OH progesterone (17OHP) and oral or vaginal micronized progesterone with cerclage for the prevention of preterm birth in women with a short cervix. METHODS: The study included 95 women with singleton gestation and cervical length (CL) ≤ 25 mm. Among these, 35 women were asymptomatic at 15-24 weeks and 60 had symptoms of threatened late miscarriage (LM) or preterm delivery (PD) at 15-32 weeks. Patients were randomized to receive dydrogesterone, 17OHP or oral/vaginal micronized progesterone; after one week of therapy 15 women underwent cerclage...
May 29, 2017: Journal of Maternal-fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/28501869/intramuscular-versus-vaginal-progesterone-administration-in-medicated-frozen-embryo-transfer-cycles-a-randomized-clinical-trial-assessing-sub-endometrial-contractions
#17
Anat Hershko Klement, Nivin Samara, Amir Weintraub, Frederic Mitri, Yaakov Bentov, Paul Chang, Dan Nayot, Robert F Casper
OBJECTIVE: The study aimed to assess whether sub-endometrial contractility is reduced by the use of intramuscular (IM) progesterone. DESIGN: This is a randomized clinical trial. Patients assigned to a medicated day 5 frozen embryo transfer (FET) were randomly allocated to "vaginal progesterone" or "IM progesterone": patients randomized to the vaginal arm were treated with 200 mg micronized progesterone 3 times daily while patients randomized into the IM progesterone arm were treated with a single daily injection of 50 mg progesterone in oil...
May 13, 2017: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/28452247/predictive-value-of-repeated-measurements-of-luteal-progesterone-and-estradiol-levels-in-patients-with-intrauterine-insemination-and-controlled-ovarian-stimulation
#18
Panagiotis Bakas, Maria Simopoulou, Maria Giner, Petros Drakakis, Perikles Panagopoulos, Nikolaos Vlahos
OBJECTIVE: The objective of this study is to assess if the difference of repeated measurements of estradiol and progesterone during luteal phase predict the outcome of intrauterine insemination. DESIGN: Prospective study. SETTING: Reproductive clinic. PATIENTS: 126 patients with infertility. INTERVENTION(S): Patients underwent controlled ovarian stimulation with recombinant FSH (50-150 IU/d)...
October 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28405121/gnrh-agonist-treatment-improves-implantation-and-pregnancy-rates-of-frozen-thawed-embryos-transfer
#19
S A Hebisha, H M Adel
OBJECTIVE: To study the effect of GnRh agonist administration prior to estrogen-progesterone preparation of the endometrium on the implantation rate in frozen-thawed embryo transfer (FET) cycles in infertile patients treated with IVF/ICSI. DESIGN: Prospective controlled study. SETTING: Private center in Alexandria, Egypt. PATIENTS: Patients undergoing frozen-thawed embryo transfer FET. INTERVENTIONS: Patients were divided into two groups, A and B...
April 2017: Journal of Obstetrics and Gynaecology of India
https://www.readbyqxmd.com/read/28333318/a-phase-iii-randomized-controlled-trial-comparing-the-efficacy-safety-and-tolerability-of-oral-dydrogesterone-versus-micronized-vaginal-progesterone-for-luteal-support-in-in-vitro-fertilization
#20
RANDOMIZED CONTROLLED TRIAL
Herman Tournaye, Gennady T Sukhikh, Elke Kahler, Georg Griesinger
STUDY QUESTION: Is oral dydrogesterone 30 mg daily (10 mg three times daily [TID]) non-inferior to micronized vaginal progesterone (MVP) 600 mg daily (200 mg TID) for luteal support in in vitro fertilization (IVF), assessed by the presence of fetal heartbeats determined by transvaginal ultrasound at 12 weeks of gestation? SUMMARY ANSWER: Non-inferiority of oral dydrogesterone versus MVP was demonstrated at 12 weeks of gestation, with a difference in pregnancy rate and an associated confidence interval (CI) that were both within the non-inferiority margin...
May 1, 2017: Human Reproduction
keyword
keyword
59383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"